Home
Knight Therapeutics Inc.

Knight Therapeutics Inc. Market Share Analysis for May 2026

Industry: N/A

Domainknighttx.com

Year Founded2014

Employees501 - 1000

Annual Revenue$200M - $500M

Knight Therapeutics Inc.

Knight Therapeutics Inc. (including company regionals)

knighttx.com

See more website traffic and engagement information

Knight Therapeutics Inc. Revenue up to May 2026 is 200M - 500M

revenue generated by Knight Therapeutics Inc. top domains

Knight Therapeutics Inc. top domains revenue over 3 years

Revenue for Knight Therapeutics Inc. top domains

knighttx.com200M - 500M

See more with Sales Intelligence

Total visits to Knight Therapeutics Inc.'s top domains

Understand Knight Therapeutics Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

knighttx.com20.6K

See more with Sales Intelligence

Avg. visit duration in Knight Therapeutics Inc.'s top domains

Analyze Knight Therapeutics Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

knighttx.com00:00:44

See more with Sales Intelligence

Avg. pageviews on Knight Therapeutics Inc.'s top domains

See how Knight Therapeutics Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

knighttx.com1.98

See more with Sales Intelligence

Knight Therapeutics Inc. top competitors by domain

Top similar sites in May 2026, ranked by their affinity

tibsovopro.comCompany NameFAQs | CCA | TIBSOVO® (ivosidenib tab...Employees> 10001HQUnited StatesAnnual revenue--Total visits18.8KN/A

Top technologies used by Knight Therapeutics Inc.

These are the website technologies, by industry, used by Knight Therapeutics Inc. top domains

Widget (5)

Twemoji

Advertising (4)

Google Adsense

Content Management System (2)

WordPress

Conversion & Analytics (2)

Google Analytics

More Technologies

6

See all

News & Signals from Knight Therapeutics Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsKnight Therapeutics Inc. launched TAVALISSE in Mexico on May 27th '26.MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) - Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE(R)(fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.[1]

NewsKnight Therapeutics Inc. has revenue of $148M.Knight reported Q1 revenue of $148.4-million, up 69% year-over-year and ahead of Uddin's $110.2-million estimate and consensus near $113.5-million.

NewsKnight Therapeutics Inc. attended event 2026 Bloom Burton & Co. Healthcare Investor Conference on Apr 15th '26.MONTREAL, April 15, 2026 (GLOBE NEWSWIRE) - Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 21, 2026, at 2:00 p.m. ET at the Metro Toronto Convention Centre (North Building) in Toronto.